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The Food and Drug Administration (FDA) is responsible for pro-
tecting and promoting the public health of US citizens. In
keeping with this mission, FDA’s Center for Devices and Radio-
logical Health (CDRH) is tasked with assuring the safety, effective-
ness, and quality of medical devices, assuring the safety of
radiation-emitting products, fostering innovation, and providing
the public with accurate, science-based information about the pro-
ducts we oversee, throughout the total product life cycle.
1 In order
to enhance our ability to fulﬁl our mission, CDRH developed a
strategic plan to identify priority areas for 2010. One of our
goals is to proactively help facilitate medical device innovation
and address unmet public health needs.
2 To accomplish this
objective, CDRH believes it is critical to leverage our regulatory
authority and unique understanding of the products we oversee,
as well as to establish strong working relationships with our
partners in the federal government and external constituencies,
and to advance innovative solutions to critical public health
challenges.
2
One example of this type of collaboration is participation by
members of CDRH’s Division of Cardiovascular Devices in the
efforts of the Valve Academic Research Consortium (VARC), an
independent group that includes members of academic research
organizations, cardiovascular professional societies (clinical and
interventional cardiology and cardiothoracic surgery), and the
medical device industry. The Valve Academic Research Consor-
tium was established in response to the burgeoning interest in
transcatheter aortic valve implantation (TAVI) by the medical com-
munity. Transcatheter aortic valve implantation represents a
potential breakthrough technology, offering a less invasive
catheter-based treatment option for patients with severe aortic
stenosis, some of whom may not be candidates for open heart
surgery. Although a less invasive option to open surgery has
many attractive features, TAVI involves highly novel devices and
presents many complex challenges in the design, conduct, and
interpretation of clinical trials.
To address some of these challenges, VARC employed a multi-
disciplinary approach to develop consensus regarding standardized
deﬁnitions for adverse events and recommendations for single and
composite endpoints that reﬂect appropriate device-, procedure-,
and patient-related safety and effectiveness measures for TAVI
clinical trials that enrol high-risk patients. This approach resulted
in a rigorous but clinically appropriate and reasonable set of rec-
ommendations. The FDA anticipates incorporating many of the
recommendations put forth in the consensus document into the
TAVI clinical trials reviewed and regulated by the Agency. As
such, we believe that the VARC document can help improve the
efﬁciency with which TAVI clinical trials are designed and executed.
We continue to encourage sponsors to contact the Agency
early in device development to begin discussions regarding speciﬁc
endpoints for studies intended to support FDA approval. While a
common set of deﬁnitions and endpoints is very helpful, critical
trial design elements may depend on the particular device and
patient population being studied. Also, many of the most difﬁcult
challenges associated with these devices involve preclinical
testing issues due to the anatomically and haemodynamically chal-
lenging aortic environment where these devices must perform well
for long periods of time. Therefore, it is extremely important that
sponsors understand FDA’s preclinical testing requirements as
early as possible so that adequate fatigue testing, ﬁnite element
analysis modelling, and animal studies can be completed for
these innovative devices. It is our hope that publication of the
VARC document will encourage sponsors and investigators to
make use of early interaction with the Agency. For this ﬁeld to
mature in the USA, it is essential that FDA, sponsors, and investi-
gators continue to collaborate closely to develop high-quality clini-
cal data that ultimately results in beneﬁts for patients.
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tance of the global approach adopted by VARC, both in terms of
geography (representatives from the scientiﬁc community in
both USA and Europe) and expertise (surgeons, interventional car-
diologists, clinical cardiologists, clinical trialists, and other allied
specialists), which we believe was instrumental to the success of
this initial undertaking. Such a process allowed for an open and
balanced discussion of complex issues. There are multiple areas
of medicine in which this collegial and comprehensive approach
would be beneﬁcial. Finally, the consensus report represents the
ﬁrst step in what promises to be a dynamic process, and the
Agency looks forward to continued involvement with VARC as
the technology and clinical application of TAVI evolves.
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